Genitourinary cancer research is incredibly promising, and real-world evidence is a key part of itRead moreFlatiron Health at ASCO Genutourinary Cancer Symposium 2026
Flatiron is excited to attend and present our research at the 2025 American Society of Clinical Oncology Genutourinary Cancer (ASCO GU) Symposium, showcasing how our bladder and prostate Panoramic datasets, now expanding to include patients from the UK and Germany, and research capabilities generate global real-world insights. Come meet our experts at booth #MR27 to learn more about how Flatiron is generating the evidence needed to guide treatment decisions, accelerate new development, and improve outcomes for patients with genutourinary cancers.
Flatiron is your trusted partner in delivering oncology evidence to support the evolving research questions across your genitourinary cancer portfolio
420K+
patients with genitourinary cancer
3
largest oncology markets represented in Panoramic data
200+
published pieces of bladder and prostate cancer research
80+
custom data and services projects delivered
Featured solutions
Real-world data
Our flexible real-world data configurations are tailored to address the specific needs of your oncology portfolio and now encompass more than 5 million patient journeys, 4 of the largest oncology markets in the world, 22+ tumor types, and multimodal data.
Real-world evidence services
Flatiron’s in-house expertise and flexible engagement models can help you generate the insights and evidence you need to advance your genutourinary cancer portfolio, from refining target product profiles, to conducting comparative effectiveness studies and supporting regulatory and HTA submissions.
Featured content
Genitourinary cancer research is incredibly promising, and real-world evidence is a key part of itRead more
.png)
Our research
Poster presentations
Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations
Author Affiliations: Flatiron Health
See this research
Abstract Number: 89
Poster Board Number: B22
Session Title: Poster Session A: Prostate Cancer
Date: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)
Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)
Author Affiliations: University of California San Diego, AstraZeneca, Merck & Co, Flatiron Health
See this research
Abstract Number: 102
Poster Board Number: C9
Session Title: Poster Session A: Prostate Cancer
Date: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)
Treatment Patterns and Survival Outcomes Among Lutetium 177 - Experienced Patients with Metastatic Castration-Resistant Prostate Cancer
Author Affiliations: Peter Mac, City of Hope, Amgen, Flatiron Health
See this research
Abstract Number: 69
Poster Board Number: B2
Session Title: Poster Session A: Prostate Cancer
Date: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)
Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbidities
Author Affiliations: Quironsalud Madrid, National & Kapodistrian University of Athens, Erasmus MC Cancer Institute, University of Sheffield, Université Paris Cité, Merck KGaA, EMD Serono, Roche, Dana-Farber Cancer Institute, Flatiron Health
See this research
Abstract Number: 666
Poster Board Number: C16
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)
Opportunities for Precision Oncology: Real-world Patterns and Disparities in FGFR3 Testing Among US Patients with Locally Advanced/Metastatic Urothelial Cancer (LA/mUC)
Author Affiliations: Eli Lilly and Company, Abramson Cancer Center, Flatiron Health
See this research
Abstract Number: 682
Poster Board Number: D6
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)
Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment
Author Affiliations: Flatiron Health
See this research
Abstract Number: 672
Poster Board Number: C22
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)
Want to learn more about how Flatiron’s Global Evidence Solutions can support research across your genitourinary cancer portfolio?
Flatiron’s industry-leading oncology solutions unlock global insights in prostate and bladder cancer research.
Contact us to learn more about Flatiron’s flexible evidence solutions